Research Papers
|
| Dishevelled-1 DIX and PDZ domain lysine residues regulate oncogenic Wnt signaling |
|
https://doi.org/10.18632/oncotarget.28089
Monica Sharma, Isabel Castro-Piedras, Fahmida Rasha, Sabarish Ramachandran, Souad R. Sennoune, Kathryn Furr, Sharilyn Almodovar, Vadivel Ganapathy, Matthew B. Grisham, Rakhshanda Layeequr Rahman, Kevin Pruitt
|
| 2234-2251 |
|
| P10s-PADRE vaccine combined with neoadjuvant chemotherapy in ER-positive breast cancer patients induces humoral and cellular immune responses |
|
https://doi.org/10.18632/oncotarget.28083
Issam Makhoul, Saddam Mohammed Ibrahim, Muhammad Abu-Rmaileh, Fariba Jousheghany, Eric R. Siegel, Lora J. Rogers, John J. Lee, Sergio Pina-Oviedo, Ginell R. Post, J. Thaddeus Beck, Thomas Kieber-Emmons, Behjatolah Monzavi-Karbassi
|
| 2252-2265 |
|
| THBS2 as a prognostic biomarker for patients diagnosed with metastatic pancreatic ductal adenocarcinoma |
|
https://doi.org/10.18632/oncotarget.28099
Phyllis A. Gimotty, Jacob E. Till, Shirsa Udgata, Naomi Takenaka, Stephanie S. Yee, Michael J. LaRiviere, Mark H. O’Hara, Kim A. Reiss, Peter O'Dwyer, Bryson W. Katona, Daniel Herman, Erica L. Carpenter, Kenneth S. Zaret
|
| 2266-2272 |
|
| Comparison of MET gene amplification analysis by next-generation sequencing and fluorescence in situ hybridization |
|
https://doi.org/10.18632/oncotarget.28092
Christina Schmitt, Anna-Alice Schulz, Ria Winkelmann, Kevin Smith, Peter J. Wild, Melanie Demes
|
| 2273-2282 |
Reviews
|
| Emerging approaches of wound healing in experimental models of high-grade oral mucositis induced by anticancer therapy |
|
https://doi.org/10.18632/oncotarget.28091
Ana Chor, Maria Adriana Skeff, Christina Takiya, Raquel Gonçalves, Marcos Dias, Marcos Farina, Leonardo R. Andrade, Valeria de Mello Coelho
|
| 2283-2299 |
Editorial
|
| Future directions for immunotherapy in meningioma treatment |
|
https://doi.org/10.18632/oncotarget.27994
John W. Rutland, Jonathan T. Dullea, Raj K. Shrivastava
|
| 2300-2301 |
|
| Clinicopathological utility of human epidermal growth factor receptor 2 (HER2)-heterogeneity for next-generation treatments of triple-negative breast cancer |
|
https://doi.org/10.18632/oncotarget.28007
Sasagu Kurozumi, Ayaka Katayama, Ken Shirabe, Jun Horiguchi, Emad A. Rakha
|
| 2302-2304 |
Corrections
|
| Correction: Tumor suppressor RARRES1 links tubulin deglutamylation to mitochondrial metabolism and cell survival |
|
https://doi.org/10.18632/oncotarget.28093
Sara Maimouni, Mi-Hye Lee, You-Me Sung, Michael Hall, Arpita Roy, Chokri Ouaari, Yoo-Seok Hwang, Justin Spivak, Eric Glasgow, Matthew Swift, Jay Patel, Amrita Cheema, Deepak Kumar, Stephen Byers
|
| 2305-2306 |
Copyright © 2026 Rapamycin Press LLC dba Impact Journals
Oncotarget ® is a registered trademark of Rapamycin Press LLC
Impact Journals ® is a registered trademark of Rapamycin Press LLC
RAPAMYCIN PRESS ® is a registered trademark of Rapamycin Press LLC
